Astrazeneca (AZN) Short term Debt (2013 - 2025)

Astrazeneca (AZN) has reported Short term Debt for 16 consecutive years, with $3.1 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, Short term Debt rose 32.82% year-over-year to $3.1 billion; the TTM figure through Dec 2025 stood at $3.1 billion (up 32.82% YoY), while the FY2025 annual figure was $3.1 billion, up 32.82% from the prior year.
• Short term Debt came in at $3.1 billion for Q4 2025 at Astrazeneca, up from $2.3 billion in the prior quarter.
• The five-year high for Short term Debt was $5.3 billion in Q4 2022, with the low at -$143.0 million in Q1 2021.
• Average Short term Debt over 5 years is $2.9 billion, with a median of $2.7 billion recorded in 2024.
• Across the five-year window, Short term Debt surged 220.12% in 2022 and sank 54.44% in 2024, its largest moves.
• Year by year, Short term Debt stood at $1.7 billion in 2021, then soared by 220.12% to $5.3 billion in 2022, then dropped by 3.48% to $5.1 billion in 2023, then sank by 54.44% to $2.3 billion in 2024, then jumped by 32.82% to $3.1 billion in 2025.
• According to Business Quant data, Short term Debt over the past three periods registered $3.1 billion, $2.3 billion, and $5.1 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.